Piper Sandler Keeps Their Buy Rating on Akoya Biosciences (AKYA)

In a report released today, David Westenberg from Piper Sandler maintained a Buy rating on Akoya Biosciences (AKYA – Research Report), with a price target of $8.00. The company’s shares closed yesterday at $4.22.

According to TipRanks, Westenberg is an analyst with an average return of -0.8% and a 43.79% success rate. Westenberg covers the Healthcare sector, focusing on stocks such as Natera, Myriad Genetics, and Exact Sciences.

Akoya Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $8.90.

Based on Akoya Biosciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $26.49 million and a GAAP net loss of $10.8 million. In comparison, last year the company earned a revenue of $21.22 million and had a GAAP net loss of $18.88 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Akoya Biosciences (AKYA) Company Description:

Akoya Biosciences Inc is an an innovative life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery and clinical research. It offers the most comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications.